Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: In vitro and in vivo studies

Monica Gunetti, Alessio Noghero, Fabiola Molla, Lidia Irene Staszewsky, Noeleen De Angelis, Annarita Soldo, Ilaria Russo, Edoardo Errichiello, Chiara Frasson, Deborah Rustichelli, Ivana Ferrero, Anna Gualandris, Massimo Berger, Massimo Geuna, Paolo Scacciatella, Giuseppe Basso, Sebastiano Marra, Federico Bussolino, Roberto Latini, Franca Fagioli

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background aims. Bone marrow (BM)-derived cells appear to be a promising therapeutic source for the treatment of acute myocardial infarction (AMI). However, the quantity and quality of the cells to be used, along with the appropriate time of administration, still need to be defined. We thus investigated the use of BM CD34+-derived cells as cells suitable for a cell therapy protocol (CTP) in the treatment of experimental AMI. Methods. The need for a large number of cells was satisfied by the use of a previously established protocol allowing the expansion of human CD34+ cells isolated from neonatal and adult hematopoietic tissues. We evaluated gene expression, endothelial differentiation potential and cytokine release by BM-derived cells during in vitro culture. Basal and expanded CD34+ cells were used as a delivery product in a murine AMI model consisting of a coronary artery ligation (CAL). Cardiac function recovery was evaluated after injecting basal or expanded cells. Results. Gene expression analysis of in vitro-expanded cells revealed that endothelial markers were up-regulated during culture. Moreover, expanded cells generated a CD14+ subpopulation able to differentiate efficiently into VE-cadherin-expressing cells. In vivo, we observed a cardiac function recovery in mice sequentially treated with basal and expanded cells injected 4 h and 7 days after CAL, respectively. Conclusions. Our data suggest that combining basal and expanded BM-derived CD34+ cells in a specific temporal pattern of administration might represent a promising strategy for a successful cell-based therapy.

Original languageEnglish
Pages (from-to)1140-1152
Number of pages13
JournalCytotherapy
Volume13
Issue number9
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Bone Marrow
Myocardial Infarction
Therapeutics
Recovery of Function
Cell- and Tissue-Based Therapy
Bone Marrow Cells
Ligation
Coronary Vessels
In Vitro Techniques
Gene Expression
Clinical Protocols
Endothelial Cells
Cell Count
Cytokines

Keywords

  • Cellular therapy
  • cytotherapy
  • stem cells
  • translational research

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Molecular Medicine

Cite this

Gunetti, M., Noghero, A., Molla, F., Staszewsky, L. I., De Angelis, N., Soldo, A., ... Fagioli, F. (2011). Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: In vitro and in vivo studies. Cytotherapy, 13(9), 1140-1152. https://doi.org/10.3109/14653249.2011.597559

Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment : In vitro and in vivo studies. / Gunetti, Monica; Noghero, Alessio; Molla, Fabiola; Staszewsky, Lidia Irene; De Angelis, Noeleen; Soldo, Annarita; Russo, Ilaria; Errichiello, Edoardo; Frasson, Chiara; Rustichelli, Deborah; Ferrero, Ivana; Gualandris, Anna; Berger, Massimo; Geuna, Massimo; Scacciatella, Paolo; Basso, Giuseppe; Marra, Sebastiano; Bussolino, Federico; Latini, Roberto; Fagioli, Franca.

In: Cytotherapy, Vol. 13, No. 9, 10.2011, p. 1140-1152.

Research output: Contribution to journalArticle

Gunetti, M, Noghero, A, Molla, F, Staszewsky, LI, De Angelis, N, Soldo, A, Russo, I, Errichiello, E, Frasson, C, Rustichelli, D, Ferrero, I, Gualandris, A, Berger, M, Geuna, M, Scacciatella, P, Basso, G, Marra, S, Bussolino, F, Latini, R & Fagioli, F 2011, 'Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: In vitro and in vivo studies', Cytotherapy, vol. 13, no. 9, pp. 1140-1152. https://doi.org/10.3109/14653249.2011.597559
Gunetti, Monica ; Noghero, Alessio ; Molla, Fabiola ; Staszewsky, Lidia Irene ; De Angelis, Noeleen ; Soldo, Annarita ; Russo, Ilaria ; Errichiello, Edoardo ; Frasson, Chiara ; Rustichelli, Deborah ; Ferrero, Ivana ; Gualandris, Anna ; Berger, Massimo ; Geuna, Massimo ; Scacciatella, Paolo ; Basso, Giuseppe ; Marra, Sebastiano ; Bussolino, Federico ; Latini, Roberto ; Fagioli, Franca. / Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment : In vitro and in vivo studies. In: Cytotherapy. 2011 ; Vol. 13, No. 9. pp. 1140-1152.
@article{e9e292b52d604ef3990e39da3791d489,
title = "Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: In vitro and in vivo studies",
abstract = "Background aims. Bone marrow (BM)-derived cells appear to be a promising therapeutic source for the treatment of acute myocardial infarction (AMI). However, the quantity and quality of the cells to be used, along with the appropriate time of administration, still need to be defined. We thus investigated the use of BM CD34+-derived cells as cells suitable for a cell therapy protocol (CTP) in the treatment of experimental AMI. Methods. The need for a large number of cells was satisfied by the use of a previously established protocol allowing the expansion of human CD34+ cells isolated from neonatal and adult hematopoietic tissues. We evaluated gene expression, endothelial differentiation potential and cytokine release by BM-derived cells during in vitro culture. Basal and expanded CD34+ cells were used as a delivery product in a murine AMI model consisting of a coronary artery ligation (CAL). Cardiac function recovery was evaluated after injecting basal or expanded cells. Results. Gene expression analysis of in vitro-expanded cells revealed that endothelial markers were up-regulated during culture. Moreover, expanded cells generated a CD14+ subpopulation able to differentiate efficiently into VE-cadherin-expressing cells. In vivo, we observed a cardiac function recovery in mice sequentially treated with basal and expanded cells injected 4 h and 7 days after CAL, respectively. Conclusions. Our data suggest that combining basal and expanded BM-derived CD34+ cells in a specific temporal pattern of administration might represent a promising strategy for a successful cell-based therapy.",
keywords = "Cellular therapy, cytotherapy, stem cells, translational research",
author = "Monica Gunetti and Alessio Noghero and Fabiola Molla and Staszewsky, {Lidia Irene} and {De Angelis}, Noeleen and Annarita Soldo and Ilaria Russo and Edoardo Errichiello and Chiara Frasson and Deborah Rustichelli and Ivana Ferrero and Anna Gualandris and Massimo Berger and Massimo Geuna and Paolo Scacciatella and Giuseppe Basso and Sebastiano Marra and Federico Bussolino and Roberto Latini and Franca Fagioli",
year = "2011",
month = "10",
doi = "10.3109/14653249.2011.597559",
language = "English",
volume = "13",
pages = "1140--1152",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment

T2 - In vitro and in vivo studies

AU - Gunetti, Monica

AU - Noghero, Alessio

AU - Molla, Fabiola

AU - Staszewsky, Lidia Irene

AU - De Angelis, Noeleen

AU - Soldo, Annarita

AU - Russo, Ilaria

AU - Errichiello, Edoardo

AU - Frasson, Chiara

AU - Rustichelli, Deborah

AU - Ferrero, Ivana

AU - Gualandris, Anna

AU - Berger, Massimo

AU - Geuna, Massimo

AU - Scacciatella, Paolo

AU - Basso, Giuseppe

AU - Marra, Sebastiano

AU - Bussolino, Federico

AU - Latini, Roberto

AU - Fagioli, Franca

PY - 2011/10

Y1 - 2011/10

N2 - Background aims. Bone marrow (BM)-derived cells appear to be a promising therapeutic source for the treatment of acute myocardial infarction (AMI). However, the quantity and quality of the cells to be used, along with the appropriate time of administration, still need to be defined. We thus investigated the use of BM CD34+-derived cells as cells suitable for a cell therapy protocol (CTP) in the treatment of experimental AMI. Methods. The need for a large number of cells was satisfied by the use of a previously established protocol allowing the expansion of human CD34+ cells isolated from neonatal and adult hematopoietic tissues. We evaluated gene expression, endothelial differentiation potential and cytokine release by BM-derived cells during in vitro culture. Basal and expanded CD34+ cells were used as a delivery product in a murine AMI model consisting of a coronary artery ligation (CAL). Cardiac function recovery was evaluated after injecting basal or expanded cells. Results. Gene expression analysis of in vitro-expanded cells revealed that endothelial markers were up-regulated during culture. Moreover, expanded cells generated a CD14+ subpopulation able to differentiate efficiently into VE-cadherin-expressing cells. In vivo, we observed a cardiac function recovery in mice sequentially treated with basal and expanded cells injected 4 h and 7 days after CAL, respectively. Conclusions. Our data suggest that combining basal and expanded BM-derived CD34+ cells in a specific temporal pattern of administration might represent a promising strategy for a successful cell-based therapy.

AB - Background aims. Bone marrow (BM)-derived cells appear to be a promising therapeutic source for the treatment of acute myocardial infarction (AMI). However, the quantity and quality of the cells to be used, along with the appropriate time of administration, still need to be defined. We thus investigated the use of BM CD34+-derived cells as cells suitable for a cell therapy protocol (CTP) in the treatment of experimental AMI. Methods. The need for a large number of cells was satisfied by the use of a previously established protocol allowing the expansion of human CD34+ cells isolated from neonatal and adult hematopoietic tissues. We evaluated gene expression, endothelial differentiation potential and cytokine release by BM-derived cells during in vitro culture. Basal and expanded CD34+ cells were used as a delivery product in a murine AMI model consisting of a coronary artery ligation (CAL). Cardiac function recovery was evaluated after injecting basal or expanded cells. Results. Gene expression analysis of in vitro-expanded cells revealed that endothelial markers were up-regulated during culture. Moreover, expanded cells generated a CD14+ subpopulation able to differentiate efficiently into VE-cadherin-expressing cells. In vivo, we observed a cardiac function recovery in mice sequentially treated with basal and expanded cells injected 4 h and 7 days after CAL, respectively. Conclusions. Our data suggest that combining basal and expanded BM-derived CD34+ cells in a specific temporal pattern of administration might represent a promising strategy for a successful cell-based therapy.

KW - Cellular therapy

KW - cytotherapy

KW - stem cells

KW - translational research

UR - http://www.scopus.com/inward/record.url?scp=80052914670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052914670&partnerID=8YFLogxK

U2 - 10.3109/14653249.2011.597559

DO - 10.3109/14653249.2011.597559

M3 - Article

C2 - 21846293

AN - SCOPUS:80052914670

VL - 13

SP - 1140

EP - 1152

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 9

ER -